A San Francisco jury has backed Illumina (NASDAQ:ILMN) in a patent infringement lawsuit against Ariosa Diagnostics pertaining to the Harmony non-invasive prenatal test (NIPT). Specifically, the jury found that Ariosa’s previous and current version of the test infringes on two Illumina patents (U.S. Patent Nos. 8,318,430 and 7,955,794) and awarded $26.7M to Illumina for damages.

The jury rejected counterclaims by Ariosa, now owned by Roche (OTCQX:RHHBY), that Illumina breached a supply agreement between the two firms by filing the litigation.

Illumina says it will seek injunctive relief to prohibit Ariosa from marketing its test.

Story from seekingalpha.com